GSK Reports Strong 2025 Performance, Reaffirms Outlooks, and Advances Robust Pipeline
GSK sits 77% above its 52-week low of $32.38.
Summary
GSK reported robust 2025 financial results with strong growth in key segments, issued positive guidance for 2026, and highlighted significant advancements in its R&D pipeline, reinforcing its long-term growth strategy.
Key Events · Earnings and Guidance · GSK
-
Strong 2025 Financial Performance
GSK delivered £32.7 billion in total sales (+7% CER) and achieved double-digit growth in Core Operating Profit (+11% CER) and Core EPS (+12% CER, 172.0p). Specialty Medicines sales grew by 17% CER, with Oncology up 43% and HIV up 11%.
-
Positive 2026 Guidance & Long-Term Outlook
The company expects 2026 turnover growth of 3-5% and Core Operating Profit/EPS growth of 7-9% (all CER). GSK also reaffirmed its 2031 sales outlook of over £40 billion.
-
Robust R&D Pipeline Progress
In 2025, GSK secured 5 major FDA approvals and initiated 7 pivotal trials. For 2026, 2 new major product approvals (bepirovirsen, tebipenem) and 5 pivotal readouts are expected, including positive results for bepirovirsen.
-
Increased Shareholder Returns
GSK declared an increased Q4 2025 dividend of 18p (66p for FY 2025) and expects 70p for FY 2026, alongside executing £1.4 billion of its £2 billion share buyback program.
Analysis · GSK · Life Sciences
This 6-K filing details GSK's strong financial performance for 2025, driven by double-digit growth in Specialty Medicines, and provides positive guidance for 2026. The company also reaffirmed its long-term sales outlook for 2031. Significant progress in the R&D pipeline, including multiple FDA approvals and anticipated key product launches in 2026, underpins future growth. Additionally, GSK announced an increased dividend and continued its share buyback program, demonstrating a commitment to shareholder returns. The report also reiterates previously disclosed strategic transactions, such as the ViiV Healthcare ownership realignment and the RAPT Therapeutics acquisition, which further strengthen the company's portfolio.
At the time of this filing, GSK was trading at $57.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $107.5B. The 52-week trading range was $32.38 to $57.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.